Abstract
ABSTRACTCandoxatril (UK‐79,300) is the orally active prodrug of candoxatrilat (UK‐73,967), the active enantiomer of (±) candoxatrilat (UK‐69,578), a potent neutral endopeptidase inhibitor. This article describes the rationale behind the use of this drug in the treatment of hypertension and chronic heart failure in humans. It further describes the pharmacokinetic and pharmacodynamics of candoxatril in preclinical animal studies, normal healthy individuals, and in patients with hypertension and chronic cardiac failure. In addition, we have described the initial results of clinical trials in hypertension and chronic cardiac failure, together with the potential future clinical developments of combined neutral endopeptidase/angiotensin converting enzyme inhibitors.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
